These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 8627534

  • 1. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents.
    Bristow LJ, Flatman KL, Hutson PH, Kulagowski JJ, Leeson PD, Young L, Tricklebank MD.
    J Pharmacol Exp Ther; 1996 May; 277(2):578-85. PubMed ID: 8627534
    [Abstract] [Full Text] [Related]

  • 2. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex.
    Bristow LJ, Hutson PH, Kulagowski JJ, Leeson PD, Matheson S, Murray F, Rathbone D, Saywell KL, Thorn L, Watt AP, Tricklebank MD.
    J Pharmacol Exp Ther; 1996 Nov; 279(2):492-501. PubMed ID: 8930150
    [Abstract] [Full Text] [Related]

  • 3. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [Abstract] [Full Text] [Related]

  • 4. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G, Rogóz Z, Wieczorek A.
    Pol J Pharmacol; 1997 Jun; 49(1):5-15. PubMed ID: 9431546
    [Abstract] [Full Text] [Related]

  • 9. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [Abstract] [Full Text] [Related]

  • 10. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A.
    Quartaroli M, Carignani C, Dal Forno G, Mugnaini M, Ugolini A, Arban R, Bettelini L, Maraia G, Belardetti F, Reggiani A, Trist DG, Ratti E, Di Fabio R, Corsi M.
    J Pharmacol Exp Ther; 1999 Jul; 290(1):158-69. PubMed ID: 10381772
    [Abstract] [Full Text] [Related]

  • 11. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine.
    Arvanov VL, Wang RY.
    J Pharmacol Exp Ther; 1999 May; 289(2):1000-6. PubMed ID: 10215680
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat.
    Nsimba SE.
    Indian J Physiol Pharmacol; 2009 May; 53(3):209-18. PubMed ID: 20329367
    [Abstract] [Full Text] [Related]

  • 17. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
    Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H.
    J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
    [Abstract] [Full Text] [Related]

  • 18. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T.
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A, Havemann-Reinecke U.
    J Neural Transm Suppl; 1995 Aug; 45():143-55. PubMed ID: 8748620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.